Dr. John Cush RheumNow
3 years 9 months ago
Retrospective study in RA shows Red cell distribution width (RDW) & absolute lymphocyte count (ALC) predict 10 yr mortality (P < 0.001); highest with both high RDW and low ALC. Data developed on 327 VA RA pts & validated on national cohort (13,914) https://t.co/aBGECUfKGH https://t.co/qkvv1PmvSB
Dr. John Cush RheumNow
3 years 9 months ago
Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/h6zpTOIuyu https://t.co/Gy3Eaqz8sM
Giant cell arteritis (GCA) has historically been a clinical diagnosis (visual loss, headache, jaw pain, scalp tenderness, etc) supported by labs and histopathology. Yet the diagnosis and classification of GCA has evolved, so much so that the ACR and EULAR have updated the 1990 Classification criteria to aid in the care and investigation of this large‐ and medium‐sized vessel vasculitis.
Dr. John Cush RheumNow
3 years 9 months ago
Study 119 SLE pts w/ SLEDAI-2K of 13.5 @Dx & 2.8 @ 1st birth. Half had 1+ flares at mean of 9 mos after birth. Pts in remission had less flares (37% vs 61%; p=0.008). SLE flares during pregnancy had more flares in F/U (76% vs 47%; p=0.019) https://t.co/3u3agu9wDj https://t.co/twj4YYclRz
Dr. John Cush RheumNow
3 years 9 months ago
Inflammatory Arthritis and Hidradenitis Suppurativa
Aa 2021 meta-analysis of 7 studies (200,361 HS patients and 385,599 controls), showed that HS patients have an increased risk for inflammatory arthritis (OR 3.44; 95% CI, 1.92–6.17)
https://t.co/JQqosM26fZ https://t.co/bXr1SSeo3p
Dr. John Cush RheumNow
3 years 9 months ago
Rheumatology was one of 6 specialties to fill > 95% during fellowship Match in 2022. Rheum filled 96.9% of 127 programs & 97.8% of 265 spots with 40 US foreign applicants (15.1%), 123 MD grads (46.4%), 66 foreign (24.9%), & 36 DO grads (13.6%) https://t.co/EqfCbkxEbS https://t.co/c12m5FrAll
Dr. John Cush RheumNow
3 years 9 months ago
Syphilis has risen 5 fold since 2001, 38 992 cases, or 11.9 per 100K in 2019. The USPSTF recommends screening in persons at increased risk. Most labs rec “reverse sequencing” w/ automated treponemal test (eg EIA), instead of RPR or VDRL1st https://t.co/vL2rkP2rO1 https://t.co/FAcijAl8LB
Dr. John Cush RheumNow
3 years 9 months ago
Tight control of proteinuria in newly diagnosed lupus nephritis
The last 3 years have been exciting times in the field of lupus nephritis (LN) with two new licensed therapies, belimumab (BAFF-inhibitor) and voclosporin (calcineurin-inhibitor).
https://t.co/InkX6I7qUm https://t.co/U1M1DtF8Id
Dr. John Cush RheumNow
3 years 9 months ago
Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE
https://t.co/ZktIKo1eVl https://t.co/dtxVXZFXpk
Dr. John Cush RheumNow
3 years 9 months ago
Xeljanz Cancer Risks Detailed
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
https://t.co/4dNRsNP7IJ https://t.co/KOjJudfdcw
Dr. John Cush RheumNow
3 years 9 months ago
Bimekizumab Efficacy in TNF-Refractory PsA
Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors.
https://t.co/78whpnLkhd https://t.co/yxwSGR3hTV
Dr. John Cush RheumNow
3 years 9 months ago
3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/VsRDg5Utik https://t.co/AMqHUveJ6e
Dr. John Cush RheumNow
3 years 9 months ago
Top 10 Pharma Revenues 2021:
1 J&J $93.77 billion (USD)
2 Pfizer $81.29 B
3 Roche $68.7 B
4 AbbVie S$56.2 B
5 Novartis $51.63 B
6 Merck $48.7 B
7 BMS $46.4 B
8 GSK $43.57 B
9. Sanofi $44.67 B
10. AstraZeneca $37.47 B
https://t.co/UBVjw2xBUF https://t.co/3MhhQzdyxG
Dr. John Cush RheumNow
3 years 9 months ago
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/HsVWlebfL2 https://t.co/dixoeHNkFQ
